Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia

Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator, as add-on treatment to antipsychotics in 161 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Ravi, Turolla, Alessio, Chinellato, Giovanni, Roy, Arjun, Hartman, Richard D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464926/
https://www.ncbi.nlm.nih.gov/pubmed/37349110
http://dx.doi.org/10.1093/ijnp/pyad035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464926/
https://www.ncbi.nlm.nih.gov/pubmed/37349110
http://dx.doi.org/10.1093/ijnp/pyad035

Ejemplares similares